Benitec Biopharma (BNTC) Q3 2026 earnings summary

Executive summary

• Focused on developing genetic medicines using a proprietary ddRNAi platform, with lead candidate BB-301 for OPMD showing durable responses in both low and high dose cohorts.

• BB-301 clinical program advanced with all six Cohort 1 patients completing 12-month follow-up and first two Cohort 2 patients safely treated, with no severe adverse events.

• Interim results presented at major scientific conferences, with pivotal study design discussions with FDA planned mid-2026.

• No approved products or product revenue; operations funded by equity and warrant issuances.

• Well-capitalized with $184.8 million in cash as of March 31, 2026.

Financial highlights

• Net loss of $11.9 million for the quarter ended March 31, 2026, compared to $14.5 million in the prior year quarter.

• Net loss for the nine months ended March 31, 2026 was $32.7 million, up from $29.1 million year-over-year.

• Operating expenses for the quarter were $13.6 million, down from $15.3 million year-over-year.

• Research and development expenses for the quarter: $6.3 million; general and administrative: $7.3 million.

• Cash and cash equivalents totaled $184.8 million as of March 31, 2026.

Outlook and guidance

• Cash and cash equivalents expected to fund operations for at least the next twelve months.

• On track to engage with FDA mid-2026 to formalize pivotal study design for BB-301.

• Updated interim clinical results for both cohorts expected in the second half of 2026.

• Anticipates continued operating losses as R&D and clinical activities expand.

• Additional financing will be required to progress product candidates to key milestones.